- Peramivir
-
- $80.00 / 1KG
-
2024-04-26
- CAS:229614-55-5
- Min. Order: 1KG
- Purity: 99.9%
- Supply Ability: 1000
- Peramivir
-
- $52.00 / 1KG
-
2024-04-24
- CAS:229614-55-5
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 5555555555
- Peramivir
-
- $45.00/ kg
-
2024-01-16
- CAS:229614-55-5
- Min. Order: 1kg
- Purity: 99.8%
- Supply Ability: 200tons/year
|
| | Peramivir Basic information |
| Product Name: | Peramivir | | Synonyms: | 3(R)-[1(S)-AcetaMido-2-ethylbutyl]-4(R)-guanidino-2(S)- hydroxycyclopentane-1(S)-carboxylic acid;PERAMIVIRUM;(1S,2S,3S,4R)-3-[(1S)-1-AcetaMido-2-ethylbutyl]-4-[(diaMinoMethylene)aMino]-2-hydroxycyclopentanecarboxylic acid;(1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid;(1R,2R,3S,4S)-3-((R)-1-acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentane-1-carboxylic acid;Peramivir USP/EP/BP;Peramivirr;3(R)-[1(S)-Acetamido-2-ethylbutyl]-4(R)-guanidino-2(S)-hydro... | | CAS: | 229614-55-5 | | MF: | C15H28N4O4 | | MW: | 328.41 | | EINECS: | 1308068-626-2 | | Product Categories: | Amines;Chiral Reagents;Intermediates & Fine Chemicals;Isotope Labelled Compounds;Pharmaceuticals;API;229614-55-5 | | Mol File: | 229614-55-5.mol |  |
| | Peramivir Chemical Properties |
| | Peramivir Usage And Synthesis |
| Uses | Peramivir is a new antiviral agent for influenza treatment; it can be used as neuraminidase inhibitor for treating human and avian influenza | | Definition | ChEBI: Peramivir is a member of the class of guanidines that is used (as its trihydrate) for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. It has a role as an antiviral drug and an EC 3.2.1.18 (exo-alpha-sialidase) inhibitor. It is a member of cyclopentanols, a member of acetamides, a member of guanidines and a 3-hydroxy monocarboxylic acid. It contains a peramivir hydrate. | | Pharmaceutical Applications | An intravenously administered neuraminidase inhibitor currently
under investigation for the treatment of influenza infections
in normal and high-risk patient populations. No drug
interactions of note have yet been identified. |
| | Peramivir Preparation Products And Raw materials |
|